JP2005508885A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508885A5 JP2005508885A5 JP2003517229A JP2003517229A JP2005508885A5 JP 2005508885 A5 JP2005508885 A5 JP 2005508885A5 JP 2003517229 A JP2003517229 A JP 2003517229A JP 2003517229 A JP2003517229 A JP 2003517229A JP 2005508885 A5 JP2005508885 A5 JP 2005508885A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- derivative
- pyrimidinone
- zebraline
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims 43
- 210000004027 cell Anatomy 0.000 claims 33
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims 16
- 108091034117 Oligonucleotide Proteins 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004414 DNA Proteins 0.000 claims 4
- 150000001733 carboxylic acid esters Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 108091029430 CpG site Proteins 0.000 claims 3
- 210000004102 animal cell Anatomy 0.000 claims 3
- 230000001580 bacterial effect Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000002538 fungal effect Effects 0.000 claims 3
- 230000011987 methylation Effects 0.000 claims 3
- 238000007069 methylation reaction Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- UCKYOOZPSJFJIZ-FMDGEEDCSA-N (4r)-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 UCKYOOZPSJFJIZ-FMDGEEDCSA-N 0.000 claims 2
- CPQQXAWTEUSBDQ-UHFFFAOYSA-N 4,6-difluoro-1h-pyrimidin-2-one Chemical class FC=1C=C(F)NC(=O)N=1 CPQQXAWTEUSBDQ-UHFFFAOYSA-N 0.000 claims 2
- 229940123974 Cytidine deaminase inhibitor Drugs 0.000 claims 2
- 230000007067 DNA methylation Effects 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 150000001735 carboxylic acids Chemical class 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 150000002170 ethers Chemical class 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 230000006607 hypermethylation Effects 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 150000003014 phosphoric acid esters Chemical class 0.000 claims 2
- 231100000588 tumorigenic Toxicity 0.000 claims 2
- 230000000381 tumorigenic effect Effects 0.000 claims 2
- QEJOIGZDWKFVCO-XLPZGREQSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=CC=C1 QEJOIGZDWKFVCO-XLPZGREQSA-N 0.000 claims 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 230000030933 DNA methylation on cytosine Effects 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 108060004795 Methyltransferase Proteins 0.000 claims 1
- 102000016397 Methyltransferase Human genes 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 150000001719 carbohydrate derivatives Chemical class 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- -1 procaridine Chemical compound 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000005740 tumor formation Effects 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30924201P | 2001-07-31 | 2001-07-31 | |
| US31143501P | 2001-08-10 | 2001-08-10 | |
| PCT/US2002/024223 WO2003012051A2 (en) | 2001-07-31 | 2002-07-30 | Inhibitor of dna methylation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010144618A Division JP5416660B2 (ja) | 2001-07-31 | 2010-06-25 | Ｄｎａメチル化の阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005508885A JP2005508885A (ja) | 2005-04-07 |
| JP2005508885A5 true JP2005508885A5 (enExample) | 2006-01-05 |
Family
ID=26976683
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003517229A Withdrawn JP2005508885A (ja) | 2001-07-31 | 2002-07-30 | Ｄｎａメチル化の阻害剤 |
| JP2010144618A Expired - Fee Related JP5416660B2 (ja) | 2001-07-31 | 2010-06-25 | Ｄｎａメチル化の阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010144618A Expired - Fee Related JP5416660B2 (ja) | 2001-07-31 | 2010-06-25 | Ｄｎａメチル化の阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8207142B2 (enExample) |
| EP (1) | EP1418949B1 (enExample) |
| JP (2) | JP2005508885A (enExample) |
| AU (1) | AU2002322805B2 (enExample) |
| CA (1) | CA2454147C (enExample) |
| WO (1) | WO2003012051A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8207142B2 (en) * | 2001-07-31 | 2012-06-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Inhibitor of DNA methylation |
| US8309302B2 (en) * | 2005-07-15 | 2012-11-13 | Abbott Laboratories | Reagents and methods for processing biological samples |
| GB0607063D0 (en) | 2006-04-07 | 2006-05-17 | Cellcentric Ltd | Compositions and methods for epigenetic modification of nucleic acid sequences in vivo |
| JP2009278867A (ja) * | 2006-09-05 | 2009-12-03 | Olympus Corp | Ｄｎａメチル化阻害作用の判定方法 |
| US20110300142A1 (en) * | 2007-05-25 | 2011-12-08 | Salford Leif G | Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants |
| JO2778B1 (en) * | 2007-10-16 | 2014-03-15 | ايساي انك | Certain Compounds, Compositions and Methods |
| US8609631B2 (en) | 2009-04-06 | 2013-12-17 | Eisai Inc. | Compositions and methods for treating cancer |
| WO2012048113A2 (en) | 2010-10-07 | 2012-04-12 | The General Hospital Corporation | Biomarkers of cancer |
| US20150167004A1 (en) * | 2012-07-09 | 2015-06-18 | Metheor Therapeutics Corporation | Oligonucleotide inhibitors of dna methyltransferases and their use in treating diseases |
| MX2016005900A (es) | 2013-11-14 | 2016-07-13 | Kainos Medicine Inc | Profarmaco mutuo que comprende acidos grasos de cadena corta y zebularina o 1'-ciano-citarabina para tratamiento del cancer. |
| EP3161159B1 (en) | 2014-06-25 | 2020-08-05 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
| CA3010610A1 (en) | 2016-01-08 | 2017-07-13 | The Brigham And Women's Hospital, Inc. | Production of differentiated enteroendocrine cells and insulin producing cells |
| PL241125B1 (pl) * | 2017-11-30 | 2022-08-08 | Gdanski Univ Medyczny | Kompozycja farmaceutyczna do zastosowania jako środek do pobudzania regeneracji lub gojenia ran |
| EP4317972A3 (en) | 2018-02-06 | 2024-03-13 | The General Hospital Corporation | Repeat rna as biomarkers of tumor immune response |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4894364A (en) | 1983-10-26 | 1990-01-16 | Greer Sheldon B | Method and materials for sensitizing neoplastic tissue to radiation |
| US5470974A (en) | 1985-03-15 | 1995-11-28 | Neu-Gene Development Group | Uncharged polynucleotide-binding polymers |
| US5607925A (en) | 1988-11-15 | 1997-03-04 | Merrell Pharmaceuticals Inc. | Treatment of carcinoma by administration of 2'-halomethylidenyl-2'-deoxynucleosides |
| US5503975A (en) | 1989-03-01 | 1996-04-02 | City Of Hope | Mechanism based inhibitors of DNA methyltransferase |
| RU2126255C1 (ru) | 1991-05-15 | 1999-02-20 | Йель Юниверсити | Способ получения противоопухолевого эффекта у млекопитающих |
| GB9311252D0 (en) | 1993-06-01 | 1993-07-21 | Hafslund Nycomed As | Cell growth regualtors |
| DE69417918T2 (de) | 1993-11-30 | 2000-01-05 | Mcgill University, Montreal | Dna methyltransferase inhibierung |
| CA2153125A1 (en) * | 1994-08-31 | 1996-03-01 | Frank Paul Abuto | Liquid-absorbing article |
| US5872104A (en) | 1994-12-27 | 1999-02-16 | Oridigm Corporation | Combinations and methods for reducing antimicrobial resistance |
| US6020139A (en) | 1995-04-25 | 2000-02-01 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
| US5871917A (en) | 1996-05-31 | 1999-02-16 | North Shore University Hospital Research Corp. | Identification of differentially methylated and mutated nucleic acids |
| US6017704A (en) | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US6011200A (en) | 1997-07-30 | 2000-01-04 | Yale University | Methods for altering the rate of plant development and plants obtained therefrom |
| AU7829398A (en) | 1997-06-09 | 1998-12-30 | University Of Southern California | A cancer diagnostic method based upon dna methylation differences |
| DE19754482A1 (de) | 1997-11-27 | 1999-07-01 | Epigenomics Gmbh | Verfahren zur Herstellung komplexer DNA-Methylierungs-Fingerabdrücke |
| US6255293B1 (en) | 1998-07-24 | 2001-07-03 | Yeda Research And Development Co., Ltd. | Prevention of metastasis with 5-aza-2′-deoxycytidine |
| ES2273672T3 (es) | 1999-03-01 | 2007-05-16 | Halogenetics, Inc. | Uso de composiciones que comprenden cldc como radiosensibilizadores en el tratamiento de enfermedades neoplasticas. |
| US6331393B1 (en) | 1999-05-14 | 2001-12-18 | University Of Southern California | Process for high-throughput DNA methylation analysis |
| US8207142B2 (en) * | 2001-07-31 | 2012-06-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Inhibitor of DNA methylation |
| EP1718150A1 (en) | 2004-02-25 | 2006-11-08 | The Government of the United States of America, represented by the Secretary, Department of Health and Human Services | Methylation inhibitor compounds |
-
2002
- 2002-07-30 US US10/485,438 patent/US8207142B2/en not_active Expired - Fee Related
- 2002-07-30 JP JP2003517229A patent/JP2005508885A/ja not_active Withdrawn
- 2002-07-30 EP EP02756825.2A patent/EP1418949B1/en not_active Expired - Lifetime
- 2002-07-30 WO PCT/US2002/024223 patent/WO2003012051A2/en not_active Ceased
- 2002-07-30 CA CA2454147A patent/CA2454147C/en not_active Expired - Fee Related
- 2002-07-30 AU AU2002322805A patent/AU2002322805B2/en not_active Ceased
-
2010
- 2010-06-25 JP JP2010144618A patent/JP5416660B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022173554A5 (enExample) | ||
| DE60038495T2 (de) | Oligonukleotid n3'-p5' thiophosphoramidate: ihre synthese und verwendung | |
| DE69427705T2 (de) | Bor-cluster enthaltende nukleoside und oligonukleoside | |
| DE69829760T3 (de) | Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga | |
| DE69934227T2 (de) | Auf Beta-Arabinose und dessen Analoga basierte Antisense-Oligonukleotide | |
| Momparler et al. | Pharmacological approach for optimization of the dose schedule of 5-Aza-2’-deoxycytidine (Decitabine) for the therapy of leukemia | |
| Thottassery et al. | Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4′-thio-2′-deoxycytidine and 5-aza-4′-thio-2′-deoxycytidine | |
| JP2019511491A5 (enExample) | ||
| JP2010528041A5 (enExample) | ||
| JP5416660B2 (ja) | Ｄｎａメチル化の阻害剤 | |
| K. Li et al. | DNA methylation as a target of epigenetic therapeutics in cancer | |
| CA3172823A1 (en) | Methods and compositions for targeting pd-l1 | |
| CN1118140A (zh) | 为提高在酸性pH的稳定性而改性的低聚核苷酸 | |
| WO2012130941A2 (de) | Perfluorierte verbindungen zum nicht-viralen transfer von nukleinsäuren | |
| US5756478A (en) | Method for reducing toxicity of D-nucleoside analogs with L-nucleosides | |
| JP2005525991A5 (enExample) | ||
| JP2015513398A5 (enExample) | ||
| JP2022550979A5 (enExample) | ||
| JPH11507642A (ja) | 局所使用のためのアシクロビル誘導体 | |
| EP0068268B1 (en) | Enhancer of anti-tumour effect | |
| AU2002322805A1 (en) | Inhibitor of DNA methylation | |
| DE4341161A1 (de) | Membrangängiger Wirkstoff zur Störung der DNA-Biosynthese | |
| CA3007357A1 (en) | Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof | |
| US20120149888A1 (en) | Synthesis of ara-2'-o-methyl-nucleosides, corresponding phosphoramidites and oligonucleotides incorporating novel modifications for biological application in therapeuctics, diagnostics, g- tetrad forming oligonucleotides and aptamers | |
| CN118302169A (zh) | 治疗癌症或血液疾病的方法 |